Literature DB >> 1389259

Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction.

T Carrel1, R Jenni, S Haubold-Reuter, G von Schulthess, M Pasic, M Turina.   

Abstract

In recent years, two pathophysiological conditions--stunned and hibernating myocardium--have been described showing how function may be depressed in myocardium that remains viable. The aims of the present study were postoperative assessment of LV function at rest and during exercise after CABG in patients with established previous myocardial infarction and impaired preoperative LV function and evaluation of preliminary experience with positron emission tomography (PET) in the preoperative identification of reversible ischaemic myocardium and its predictivity in postoperative functional improvement. We studied 23 patients with preoperative LV function under 45%. Echocardiography and complete heart catheter were performed pre- and postoperatively. PET was performed in all patients preoperatively. In 21 patients with patent grafts, CABG significantly improved systolic and diastolic function during exercise and at rest. EF improved from 34% +/- 14% to 52% +/- 11% at rest and from 31% +/- 14% to 58% +/- 13% during exercise (P less than 0.01). Time constant of diastolic relaxation was significantly reduced after revascularization. In 2 patients with pathological findings on postoperative coronarangiography, EF remained unchanged. Both global and regional contractility improved following surgery. Regional analysis indicated that improved EF at rest occurred in regions developing ischaemia during exercise before CABG and in regions showing typical mismatch in 82Rubidium-2-fluoro-2-desoxyglucose suggesting the presence of hibernating myocardium.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1389259     DOI: 10.1016/1010-7940(92)90244-r

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  18 in total

1.  Holmium Laser-Induced Coronary Thrombolysis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  PET myocardial perfusion and glucose metabolism imaging: Part 2-Guidelines for interpretation and reporting.

Authors:  Heinrich R Schelbert; Robert Beanlands; Frank Bengel; Juhani Knuuti; Marcelo Dicarli; Josef Machac; Randolph Patterson
Journal:  J Nucl Cardiol       Date:  2003 Sep-Oct       Impact factor: 5.952

3.  Factors influencing predictive value of FDG imaging for evaluating myocardial viability.

Authors:  Jamshid Maddahi
Journal:  J Nucl Cardiol       Date:  2004 Sep-Oct       Impact factor: 5.952

Review 4.  Radionuclide techniques for the assessment of myocardial viability.

Authors:  E Skoufis; A I McGhie
Journal:  Tex Heart Inst J       Date:  1998

Review 5.  The role of cardiac PET in translating basic science into the clinical arena.

Authors:  Paco E Bravo; Frank M Bengel
Journal:  J Cardiovasc Transl Res       Date:  2011-05-15       Impact factor: 4.132

6.  Clinical cardiac PET: quo vadis?

Authors:  H R Schelbert; J Maddahi
Journal:  J Nucl Cardiol       Date:  1994 Nov-Dec       Impact factor: 5.952

Review 7.  [Examination of myocardial perfusion with positron emission tomography: a clinically useful and valid method?].

Authors:  J vom Dahl
Journal:  Herz       Date:  1997-02       Impact factor: 1.443

Review 8.  Transfer from PET to SPET in cardiology, but the unit of reference is still the patient.

Authors:  O Schober; E Moser
Journal:  Eur J Nucl Med       Date:  1994-06

9.  Establishing an approach for patients with recent coronary occlusion: identification of viable myocardium.

Authors:  R S Beanlands; M Labinaz; T D Ruddy; J F Marquis; W Williams; M LeMay; L A Laramee; E O'Brien; S A Kearns; M Aung; H Johansen; L A Higginson
Journal:  J Nucl Cardiol       Date:  1999 May-Jun       Impact factor: 5.952

Review 10.  Noninvasive assessment myocardial viability: current status and future directions.

Authors:  Kevin C Allman
Journal:  J Nucl Cardiol       Date:  2013-06-15       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.